Single and dual immunohistochemical staining techniques were used to assay the effects of disruption of brain stem catecholaminergic inputs on corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) immunoreactivity in parvocellular neurosecretory neurons of the paraventricular nucleus of the hypothalamus (PVH) in normal and in adrenalectomized (ADX) rats treated with dexamethasone or vehicle. The results may be summarized as follows: (1) In adrenally intact rats, confirmed unilateral transection of ascending catecholaminergic pathways near their origins in the medulla produced a decrement in the number of CRF-immunoreactive cells that could be detected on the side of the brain ipsilateral to the cut. No effect on AVP immunoreactivity in the parvocellular division of the PVH was evident. Staining for both peptides in terminals in the external lamina of the median eminence tended to show modest decreases on the lesioned side of the brain. Compatible results were obtained in comparing the effects of bilateral transections with controls. (2) Unilaterally lesioned ADX rats treated with vehicle showed the expected enhancement in CRF immunostaining in the parvocellular division of the PVH, though the response on the side ipsilateral to the lesion was blunted relative to that seen contralaterally; the effect of ADX on AVP immunoreactivity on the ipsilateral side was more markedly reduced, but still showed evidence of enhancement (i.e., could be colocalized in some CRF immunoreactive perikarya). (3) Unilaterally lesioned ADX rats treated with dexamethasone showed no evidence of enhanced CRF or AVP immunoreactivity in perikarya or terminals on either side of the brain. The generally lower levels of staining for both peptides seen on the lesioned side across conditions suggest that the effect of interruption of ascending catecholaminergic pathways on peptide dynamics in the PVH is dissimilar to that of ADX, is manifested via different mechanisms, and that at least some types of feedback inhibition of corticotropin-releasing peptides by adrenal steroids do not require intact catecholaminergic inputs to be exhibited.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.